TGen's platform.org social media study has been nominated as a finalist for a prestigious international social impact award
San Diego, California, will play host to the Translational Genomics Research Institute (TGen) and other top leaders in the social sector from May 2-3, 2014, as they gather for the CLASSY Awards, the largest social impact awards ceremony in the United States.
The event, held at the Marriott Marquis, drives collaboration around solving social problems, and this year, TGen is a finalist for their innovative work in the investigation of Alzheimer's disease.
TGen, a Phoenix, Arizona-based non-profit organisation, is renowned for its focus on genomic research and its applications in various diseases, including neurological disorders like Alzheimer's. Their work is in the field of cutting-edge translational research.
Their approach to Alzheimer's research involves several key strategies:
1. Genomic Analysis: TGen analyses genomic data to understand genetic factors contributing to Alzheimer's disease. This includes studying genetic variants, mutations, and their impact on disease progression.
2. Data Sharing and Collaboration: TGen facilitates collaboration among researchers by providing access to large datasets and creating tools for data analysis. This collaborative environment helps accelerate research findings.
3. Translational Research: TGen might focus on translating genomic insights into clinical applications, such as developing new diagnostic tools or therapeutic strategies.
4. Public Awareness and Education: By engaging with the public and promoting awareness about genetic contributions to Alzheimer's, TGen can help raise support for research efforts.
In addition to their ongoing research, TGen has launched a web-based scientific study called the TGen platform, which aims to better understand the processes of our brain learning and remembering items of information. The TGen platform also encourages public participation in a 10-minute, anonymous test to contribute to a greater understanding of Alzheimer's. Over 28,000 volunteers have already taken the test, with a goal of gathering results from as many as 1 million participants.
Alzheimer's disease is a significant socioeconomic issue, affecting more than 5 million Americans, being the 6th leading cause of death in the U.S., and costing the nation over $200 billion annually to treat. The CLASSY Awards, an annual event recognising the world's greatest champions of social progress, highlights the importance of organisations like TGen in addressing this issue.
Steve Yozwiak, TGen's Senior Science Writer, is available for contact upon request. For more information about TGen and their work, visit their website at www.tgen.org. The winners of the CLASSY Awards are determined by a panel of experts representing various fields. This year's awards ceremony promises to be a significant event in the ongoing fight against Alzheimer's disease.
- The Translational Genomics Research Institute (TGen), a finalist for the CLASSY Awards 2014, is recognized for its work in neurogenomics, particularly in the investigation of Alzheimer's disease and other mental health and neurological disorders.
- TGen's work in the field of science encompasses genomic analysis, data sharing and collaboration, translational research, and public awareness and education, all of which aim to advance medical-conditions like Alzheimer's disease and promote health-and-wellness.
- TGen's innovative approach to Alzheimer's research includes analyzing genomic data to understand its implications on disease progression, collaborating with other researchers to accelerate findings, translating genomic insights into clinical applications, and raising public awareness about genetic contributions to the disease.
- In addition to its work on Alzheimer's, TGen has launched the TGen platform, a website-based scientific study designed to better comprehend the processes of the brain in learning and remembering. This platform encourages public participation in an anonymous 10-minute test, with the goal of garnering results from up to 1 million participants to aid in the understanding of Alzheimer's.
